Objectives To determine whether genetic variation within genes related to the Toll-like
receptor, inflammasome and interferon-γ pathways contributes to the differences in …

Objective Many patients with rheumatoid arthritis (RA) benefit from tumor necrosis factor-α
blocking treatment (anti-TNF), but about one third do not respond. The objective of this study …

Objective To determine whether genetic variation within genes integral to the Toll-like
receptor (TLR) and NFκB signalling systems, two cardinal regulators of inflammatory and …

Background Several studies point to a role of Toll-like receptors (TLRs) in the development
of rheumatoid arthritis (RA). We investigated if genetic variants in TLR genes are associated …

Objective Recently, two genome-wide association studies identified single nucleotide
polymorphisms (SNPs) significantly associated with the treatment response to tumor …

Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful
in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50 …

Introduction In this study, our aim was to elucidate the role of four polymorphisms identified
in a prior large genome-wide association study (GWAS) in which the investigators analyzed …

Additional studies are required to investigate the genetic basis of response to anti-TNF
therapy. These studies should include an unbiased search of DNA variation across the …

Objective Anti–tumor necrosis factor (anti‐TNF) agents are successful therapies in
rheumatoid arthritis (RA); however, inadequate response occurs in 30–40% of patients …

Background Recent research suggests that genetic variants in the tumor necrosis factor
receptor 2 (TNFRSF1B) gene may have an impact on susceptibility to rheumatoid arthritis …